Short answer
Dexcom (DXCM) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results for quarter ended March 31, 2026.
Dexcom 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results for quarter ended March 31, 2026
- Press release furnished as Exhibit 99.1, containing financial results and additional company information
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $1.192B, up 15% reported and 12% organic, with international growth 26% reported
- GAAP operating margin 21.4% versus 12.9%, signaling substantial operating leverage and improved profitability
- GAAP diluted EPS $0.51 versus $0.27, while non-GAAP EPS reached $0.56 versus $0.32
- 2026 revenue guidance reiterated at $5.16B-$5.25B, with non-GAAP operating margin raised to 23%-23.5%
- Cash, equivalents and marketable securities totaled $2.42B, with the revolving credit facility undrawn
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Dexcom 8-K filings
Get the next DXCM 8-K as it lands
Follow DXCM for push alerts, or ask the research agent what this filing means.